Get started
Author

Dawn DePaolo

Observed names: D. Depaolo, Dawn Depaolo, Dawn M. DePaolo, Dawn M. Depaolo
OpenAlex ID: A5019400643
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors
2014 · Nuttapong Ngamphaiboon, Grace K. Dy, et al. · Investigational New Drugs · 46
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism
2006 · Kena C. Miller, Swaminathan Padmanabhan, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
2017 · Sidra Anwar, Wei Tan, et al. · Cancers · 11
PDF
Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens.
2007 · Sikander Ailawadhi, Terry L. Mashtare, et al. · Blood · 11
Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.
2006 · Asher Alban Chanan-Khan, Sundar Jagannath, et al. · Blood · 11
Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma
2008 · Asher Alban Chanan-Khan, Mecide Gharibo, et al. · Blood · 8
Low-Dose Prednisone Decreases the Severity but Not the Frequency of Lenalidomide Associated Tumor Flare Feaction (TFR) in Chronic Lymphocytic Leukemia (CLL) Patients.
2006 · Laurie Musial, Kena C. Miller, et al. · Blood · 5
Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.
2005 · Laurie DiMiceli, Kena C. Miller, et al. · Blood · 5
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.
2007 · Asher A. Chanan-Khan, Kena C. Miller, et al. · Blood · 4
Evaluation of Quality-of-life (QoL) in patients(pts) with advanced solid tumors as screening tool during phase 1 clinical trial recruitment- risk assessment for adverse events and subject replacement.
2015 · Sidra Anwar, Wei Tan, et al. · Journal of Clinical Oncology · 2
Prednisone (P) prophylaxis decreases incidence and severity of lenalidomide (L) induced flare reaction (flr) in patients with relapse (rel) or refractory (ref) chronic lymphocytic leukemia
2006 · L. Musial, K. Miller, et al. · Journal of Clinical Oncology · 2
Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.
2007 · Dawn DePaolo, Kena C. Miller, et al. · Blood · 1
bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib.
2007 · Sikander Ailawadhi, Terry L. Mashtare, et al. · Blood · 1
Weight Adjusted Low-Dose Warfarin Decreases the Incidence of Thalidomide (T) Associated Venous Thromboembolism (VTE) in Patients (pts) with Multiple Myeloma (MM) and Waldenstroms Macroglobulinemia (WM).
2006 · Kena C. Miller, Rami Manochakian, et al. · Blood · 1
Incidence, Clinical Presentation and Outcome of Secondary Multiple Extramedullary Plasmacytomas: Experience at Roswell Park Cancer Institute.
2006 · Rami Manochakian, Kena C. Miller, et al. · Blood · 1
Lenalidomide Associated Tumor Flare Reaction Correlates with Clinical Response in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
2008 · Taimur Sher, Mehul Patel, et al. · Blood
Incidence of venous thromboembolic (VTE) in chronic lymphocytic leukemia (CLL) patients (pts) treated with immunomodulating agents (IMiDs)
2006 · D. Depaolo, K. Miller, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 132
H-index: 6
I10-index: 5
Year
Topic
Type